Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-study screening performed according to section 7.1~* Unilateral primary carcinoma of the breast, confirmed histologically by core or tru-cut biopsy. Fine-needle aspiration is not sufficient. Incisional biopsy is only allowed if less than 20% of the tumor is excised.~* Two-dimensionally measurable (mammography, ultrasound, or MRI) breast tumor~* Primary tumor \>= 2 cm in largest diameter by either palpation, sonography or mammography, or breast MRI. In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.~* No evidence of distant metastases~* Life expectancy of at least 10 years, disregarding the diagnosis of cancer.~* Karnofsky index \>= 70%.~* Age 18 years or older.~* Adequate hematological, renal, and hepatic function (WBC \> 4000, platelets \> 100 000, bilirubin, serum creatinine and transaminases within 1.5 × upper normal range).~* Evidence of normal cardiac function (with or without medication) from the patient history and from electrocardiography. Normal function is confirmed by echocardiography or multiple gated acquisition (MUGA) scan.~* Negative pregnancy test and appropriate nonhormonal contraception in fertile women. Intrauterine pessaries with progestogens are allowed.~* Written informed consent and assumed compliance for therapy and follow up of the patients.~* Consent of patient, pathologist and investigator to supply tumor material of biopsy and surgery for central pathologic evaluation and examination of predictive factors.~Exclusion Criteria:~* Locally advanced (stage T4), bilateral, metastatic, or inflammatory breast cancer. If one of these conditions is suspected, it has to be excluded before enrollment into study.~* Previous treatment for breast cancer, including surgery, radiation, cytotoxic, or endocrine treatments.~* Previous malignancy other than breast cancer or noninvasive breast cancer if the disease-free interval is less than 10 years.~* Previous cytotoxic treatment for any condition.~* Preexisting neurotoxicity greater than grade II.~* Active infection or other significant illness that could influence the tolerability of treatment.~* Current treatment with sex hormones (treatment has to be discontinued before the start of systemic therapy).~* Psychiatric illness or drug addiction that would preclude obtaining informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADOC x 4 + Tam 20 (Type: EXPERIMENTAL): Adriamycin will be given at a dose of 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles. Adriamycin will be administered as a short i.v. infusion over 15 minutes, followed immediately by a 1-hour infusion of docetaxel diluted in 250 mL NaCl. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
- AC x 4 - Doc x 4 + Tam 20 (Type: EXPERIMENTAL): Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete